Jurriaan M J L Brouwer, Marga Nijenhuis, Bianca Soree, Henk-Jan Guchelaar, Jesse J Swen, Ron H N van Schaik, Jan van der Weide, Gerard A P J M Rongen, Anne-Marie Buunk, Nienke J de Boer-Veger, Elisa J F Houwink, Roos van Westrhenen, Bob Wilffert, Vera H M Deneer, Hans Mulder
The Dutch Pharmacogenetics Working Group (DPWG) guideline presented here, presents the gene-drug interaction between the genes CYP2C19 and CYP2D6 and antidepressants of the selective serotonin reuptake inhibitor type (SSRIs). Both genes' genotypes are translated into predicted normal metabolizer (NM), intermediate metabolizer (IM), poor metabolizer (PM), or ultra-rapid metabolizer (UM). Evidence-based dose recommendations were obtained, based on a structured analysis of published literature. In CYP2C19 PM patients, escitalopram dose should not exceed 50% of the normal maximum dose...
October 2022: European Journal of Human Genetics: EJHG